AgomAb Therapeutics NV (AGMB)
NASDAQ: AGMB · Real-Time Price · USD
5.82
-0.10 (-1.69%)
At close: Nov 18, 2026, 4:00 PM EST
5.70
-0.12 (-2.06%)
After-hours: Nov 18, 2026, 7:56 PM EST
AgomAb Therapeutics NV Employees
AgomAb Therapeutics NV had 62 employees as of December 31, 2025. The number of employees increased by 4 or 7.27% compared to the previous year. That makes AgomAb Therapeutics NV the 33,997th largest employer in the world and 4,485th in the United States.
Employees
62
Change (1Y)
4
Growth (1Y)
7.27%
Revenue / Employee
n/a
Profits / Employee
-$1,503,706
Market Cap
286.62M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 62 | 4 | 7.27% |
| Dec 31, 2024 | 58 | 24 | 70.00% |
| Dec 31, 2023 | 34 | 33 | 3,300.00% |
| Dec 31, 2019 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 754 |
| ProKidney | 231 |
| Kyverna Therapeutics | 172 |
| Enanta Pharmaceuticals | 120 |
| Scribe Therapeutics | 82 |
| Larimar Therapeutics | 71 |
| Altimmune | 57 |
| X4 Pharmaceuticals | 45 |
AGMB News
- 14 days ago - Agomab to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 19 days ago - Agomab Therapeutics NV trading resumes - TheFly
- 19 days ago - Agomab Therapeutics NV trading halted, volatility trading pause - TheFly
- 5 weeks ago - Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease - GlobeNewsWire
- 6 weeks ago - AgomAb Therapeutics NV Transcript: Study result - Transcripts
- 6 weeks ago - AgomAb Therapeutics NV Press release: Study result - Filings
- 6 weeks ago - AgomAb Therapeutics NV Slides: Study result - Filings
- 6 weeks ago - Agomabâs ontunisertib shows positive results in Crohnâs Disease study - TheFly